Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 169.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
168.00 170.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -4.79 -3.55 338
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 169.00 GBX

Synairgen (SNG) Latest News

More Synairgen News
Synairgen Investors    Synairgen Takeover Rumours

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
22/1/202107:11SNG001; a potential treatment for Covid 1933,443
21/1/202123:20Synairgen - a potential cure for Covid 19?17,410
21/1/202121:21Bullshit free zone124
20/1/202121:58Synairgen - no cure for gambling losers.373
12/1/202111:12Join Guild4

Add a New Thread

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-21 17:30:00167.797,20012,081.12O
2021-01-21 17:29:43170.605,0008,529.82O
2021-01-21 17:28:42171.3210,00017,131.50O
2021-01-21 17:25:30169.274,7197,987.62O
2021-01-21 17:25:01169.277,01411,872.25O
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 169p.
Synairgen Plc has a 4 week average price of 126p and a 12 week average price of 75p.
The 1 year high share price is 259p while the 1 year low share price is currently 7p.
There are currently 199,914,402 shares in issue and the average daily traded volume is 3,425,648 shares. The market capitalisation of Synairgen Plc is £337,855,339.38.
mirabeau: With vaccine roll-outs underway, what does the future hold for Covid-19 treatment? Virus medicine still needed, Aim-traded biotech group Synairgen suggests January 14, 2021 The world still needs Covid-19 treatments even as vaccines are rolled out, a UK biotech company has argued, flagging the potential risks of virus mutations and ineffective jabs as many countries grapple with surging case numbers. Management at Aim-traded Synairgen stressed the importance of medicines this week as the company, which was spun out of Southampton University, announced the start of late-stage trials for its immunosuppressant drug ‘SNG001’. “We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2 [Covid-19]”, chief executive Richard Marsden said in a statement on Wednesday. “It is possible that the virus will mutate to the point where the vaccines are ineffective,” Mr Marsden told Investors’ Chronicle. While vaccine developers could make small adjustments to existing recipes to adapt to new virus variants, they would still need to roll out the updated version. “You’re always going to be chasing the virus”, Mr Marsden said. Vaccine uptake will also vary around the world, he noted, meaning some people might not be protected and will still need treatment if they are infected. He added that Synairgen’s drug “could be useful every year” for a range of respiratory viruses and it “could be stockpiled for the next outbreak”. Escalating pressures on the NHS Mr Marsden’s comments come as Westminster strives to offer a first shot of vaccine to four priority groups in the UK by 15 February, including the elderly and those who are clinically extremely vulnerable. Encouragingly, more than 2.6m people had already been vaccinated as of 12 January. But the government’s ambitious target is set against an increasingly precarious backdrop, with soaring virus cases and extreme pressure mounting on the NHS as infections translate into hospital admissions. More than 3.2m people in the UK have now tested positive for the virus. At the last count, 36,000 people were in hospitals with Covid-19 and nearly 3,500 of those patients required ventilation. Moreover, even if the most at-risk demographics are inoculated as planned, tens of millions of citizens will still have to wait months to reach the front of the vaccine queue. Urgent review of medicine Little wonder, perhaps, that authorities on both sides of the Atlantic appear to agree with Mr Marsden – at least for now – that treatment remains vitally important. Synairgen’s drug trial is classified as an ‘Urgent Public Health’ study in the UK and has been granted ‘Fast Track’ status in the US, as both countries strive to quell soaring infection levels while managing complex vaccination programmes hampered by limited supplies. Greater chance of improvement for hospitalised patients SNG001 is an inhaled version of the immunosuppressant drug interferon beta, administered via a nebuliser. Interferon beta is a naturally occurring antiviral protein. It “is a bit like the conductor of an orchestra”, Mr Marsden said; “it drives hundreds of processes all designed to counter viruses”. But Covid-19 suppresses the production of interferon beta “as its strategy to evade the immune system”. Delivering SNG001 straight to the lungs is equivalent to “dropping the drug straight into the battleground”, according to Mr Marsden. Synairgen’s phase three trial will take place across 20 countries, enrolling 610 patients who need supplemental oxygen. Early studies of SNG001 indicated that it lowers patients’ chances of developing severe disease by almost four-fifths. Mid-stage trial data published in the Lancet Respiratory Medicine journal last November suggested that when hospitalised Covid-19 patients received SNG001, they “had greater odds of improvement and recovered more rapidly”. Rollercoaster shares Shares in Synairgen soared last July on positive early trial news. But they have since endured a rollercoaster ride, potentially a sign of fluctuating scepticism about the need for treatments as successful jabs emerge. Indeed, the group’s share price was knocked last autumn when encouraging data emerged about the efficacy of both the Pfizer (US:PFE)/ BioNTech (US:BNTX) vaccine and the shot developed by Moderna (US:MRNA). Its market value started climbing again in early December, taking overall gains since the summer to roughly 380 per cent. Challenges of scaling up Market watchers may also question how far Synairgen is able to accelerate manufacturing if SNG001 is approved. The group is still relatively small – valued at roughly £330m on London’s junior market. Scale is required if SNG001 is to make a difference to the outlook for coronavirus treatment. Conveniently the recipe for making interferon beta “is well understood”, Mr Marsden said, despite being complex. Synairgen has a partnership with a company in Germany and a second manufacturing source in the US “just to cope with the potential demand”. The group is also working with two companies for fill-finish activities: Catalent Biologics (US:CTLT) and Thermo Fisher (US:TMO). “It’s all about contingency”, Mr Marsden said, noting the group also has two partnerships for aerosol delivery systems. Financial risk Clinical trials are expensive; arguably more of a risk for a small company. “A huge amount of investment has gone into getting this programme to where it is,” Mr Marsden said. Synairgen has spent roughly £100m on its coronavirus drug trials so far, he said, helped by fundraisings last year. In turn, “the strategy is to provide something that is good value for money,” Mr Marsden said, although “until we get data from the phase three trial, we won’t be able to set a price”. He added that US biotech group Gilead’s (US:GILD) antiviral remdesivir drug “has probably set a good precedent for a pricing point”. Gilead announced last June that it would charge $390 per vial. Diverse treatment landscape Remdesivir was made available on the NHS last year. And despite debate about its effectiveness in treating coronavirus patients, demand has remained strong during the latest surge of infections; Gilead raised its full-year guidance earlier this month. But the treatment landscape extends beyond the not-yet approved SNG001 and remdesivir. Last June the UK government greenlighted the relative cheap and accessible steroid dexamethasone as the world’s first treatment proven to reduce the risk of death from Covid-19. And Westminster said recently that patients admitted to intensive care units with Covid-19 would receive tocilizumab and sarilumab – drugs found to reduce the relative risk of death by nearly a quarter when administered within 24 hours of entering the ICU. Both drugs were already typically used to treat another illness, rheumatoid arthritis – indicating, perhaps, that further repurposing of medicines may follow, helping to tackle the coronavirus crisis as well as other potential disease outbreaks on the horizon.
wetdream: Nortic 007, What's your take on the daily price action? Seems like the ATs sell regardless of actual share price What’ll it take to break the pattern?
oilhunter2020: Hi Northern, I acted in the opposite way. I topped up yesterday because the chart says it most probably goes further up. And thats what it looks like at the moment. I see it with high risk to miss the train if somebody sells the complete SNG position. With some troubles with the vaccines, missing willingness to use the vaccine and the several virus mutations, the public and scientists are going to cry for alternatives soon. And here SNG is in the pole position imho. Forget the volatility in this stock. What counts is the end result and that will be the market access of SNGs inhaler! All imho of course.
jjmills56: Interesting that Azn share price is down on the day they receive approval for their vaccine ....,as SNG0001 is effective in helping reduce length of stay in hospitals / hospitalizaciones so there should be a positive correlation between hospitalisation rates and share price : as hospitalizations rise so should share px but the reverse appears to be happening ! Why ?
allin: Its not Marsden fault. Sng is a tiny company. They had to work with regulators to redesign phase3 trials...hence delay.Maybe if you spent a day in sng might get a clearer picture.Sng has already made the drug available via compassionate use. Its up to the powers that be to accept and use now.It might be unfair to criticize sng.
allin: Nothing exciting here..just normal progression of share price. Sng has nothing to inform the market else there would be rns.
sloppyjoe2: "SNG will be huge and all those who didn’t take advantage of these silly low share price will be kicking them self. I’ve managed to top up twice since, once at 176 the other at180" so you haven't managed to top up at these 'silly low' prices? Presumably you'll be kicking yourself... "I’ve managed to top up twice since" since what?
nasnas1: Not long to go now, SNG will be huge and all those who didn't take advantage of these silly low share price will be kicking them self. I've managed to top up twice since, once at 176 the other at180. GL all, patience will prevail
nasnas1: SNG will announce a much safer vaccine with no side effects - there manipulating the share price - top up and hold this will fire in no time and ignore the nose.
dafad: Telegraph Tip Today 06:47 Yes it is a tip for SNG. Here is the article: ‘The advent of three viable coronavirus vaccines is great news – unless, like London-quoted Synairgen, you make treatments for the disease. On Nov 9, when the success of the Pfizer/ BioNTech vaccine was announced, shares in the firm fell by 39pc. They had jumped more than fivefold on July 20, when the success of its own treatment for Covid-19 in hospital trials was reported. It is easy to see investors’ logic: if we are all going to be vaccinated against the virus over the next few months, there will be far fewer people admitted to hospital with the disease and much less need for treatments. That may be true. But the success against coronavirus of Synairgen’s treatment, a drug called interferon beta in a form delivered directly to the lungs, suggests that it could be effective against other respiratory diseases that we cannot expect to disappear in the next year or so. This at least is the view of one fund manager Questor spoke to and also of analysts at Numis, the broker. Now stockbrokers’ analysts can get carried away so perhaps we should take Numis’s share price target of 990p – more than 11 times the current price – with a pinch of salt. But the stock, which is quoted on Aim, may be worth a flutter with a small slice of your Isa or pensio
Synairgen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210122 07:17:47